Consequently, utilizing immune checkpoint blockade, including PD-1 antibodies, PD-L1 antibodies, CTLA-4 antibodies, and others, emerges as a strategy to combat prion diseases by enhancing the adaptive immune system (Figure 1, right). This evidence concerns the gene PDCD1 and prion disease.